Page not found

×

Warning message

Your search used too many AND/OR expressions. Only the first 7 terms were included in this search.

Search results

  1. Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

    ... promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at ... compared to the mGlu2 action, the group has developed a Tool compound. This mGlu3 NAM Tool Compound, used for proof of concept studies, has ...

    cttc_admin - 01/23/2024 - 4:43pm

  2. Small Molecule-GIRK Potassium Channel Modulators That Are Anxiolytic Therapeutics

    ... therapeutic intervention. Proof of Concept Tool Compound ML297 Description & Novel features ML297 (VU0456810) is a small molecule compound ...

    cttc_admin - 01/23/2024 - 1:38pm

  3. Vanderbilt-discovered drug candidate for Parkinson’s disease enters clinical trials

    ... development of AP-472—a best-in-class mGlu4 PAM—and a novel, non-dopaminergic approach for the treatment of Parkinson’s disease,” ... issues. Words cannot describe the excitement of seeing a compound sketched on a whiteboard in the lab now poised for studies in ...

    sommers - 10/07/2021 - 8:52am

  4. Vanderbilt engineering professor’s company makes successful first-in-human clinical study using novel device for endoscopic surgery

    ... first-in-human clinical study using its innovative technology that radically improves minimally invasive endoscopic surgery. ... U.S. Food and Drug Administration. Webster said the new technology answers the  FDA’s call  to transition to duodenoscopes with ...

    sommers - 08/07/2023 - 9:33am

  5. Bifunctional Small Molecule Compound Technology that Modulates Protein-Protein Interactions

    When:  Sunday, March 31, 2024 - 12:00am Daiichi Sankyo is looking for bifunctional small molecules that can inhibit target protein function through protein-protein interactions (PP...

    cttc_admin - 03/14/2024 - 6:09pm

  6. Tech Connect, Vol. 6, Issue 7: Collaboration seeks to develop new therapies for bone and other diseases

    ... Manager of Biotech Licensing in the  Vanderbilt Center for Technology Transfer & Commercialization , facilitated the agreement with La ... lipid peroxidation 9,127,005    Isoform selective phospholipase D inhibitors 9,125,895   Anti-factor ...

    steelmk - 11/15/2016 - 4:11pm

  7. Tech Connect, Vol. 7, Issue 3: CTTC launches Startup Vanderbilt's Pre-Flight Program

    ... Vanderbilt” initiative, the Vanderbilt Center for Technology Transfer and Commercialization and the Vanderbilt Innovation Center, ... motion of the surgeon’s hands to the tool’s "hands". The novel user interface approach provides a natural mapping of motion from the ...

    steelmk - 11/10/2016 - 7:45am

  8. Fused in Sarcoma (FUS) Nuclear Translocation Inhibitors for Preventing Fibrosis

    ... expression of the tyrosine phosphorylated ribonucleoprotein Fused in Sarcoma (FUS) to control the production of collagen in patients that ... or initial development of fibrotic diseases. Technology Description The research team has found that one of the key ...

    cttc_admin - 02/07/2023 - 4:12pm

  9. Discovery Vanderbilt invests in three faculty-initiated startups: HeroWear, IDBiologics and Virtuoso

    ... the  Center for Rehabilitation Engineering and Assistive Technology  by  Karl Zelik , associate professor of mechanical ... evaluation, potential licensing and clinical development as novel medicines that could treat COVID-19 or prevent infection from the ...

    sommers - 05/23/2023 - 12:14pm

  10. Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University

    ... or the “Company”) , a precision oncology company with a novel phosphoprotein and protein assay for breast cancer, today announced that ... and protein biomarker platform and LDTs, Theralink’s technology targets multiple areas of oncology and drug development. In addition ...

    sommers - 04/24/2023 - 1:45pm